- Home
- SYRE vs BAK Comparison
SYRE vs BAK Comparison
Compare SYRE & BAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- BAK
- Stock Information
- Founded
- SYRE 2013
- BAK 1972
- Country
- SYRE United States
- BAK Brazil
- Employees
- SYRE N/A
- BAK N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- BAK Major Chemicals
- Sector
- SYRE Health Care
- BAK Industrials
- Exchange
- SYRE Nasdaq
- BAK Nasdaq
- Market Cap
- SYRE 1.1B
- BAK 1.1B
- IPO Year
- SYRE 2016
- BAK N/A
- Fundamental
- Price
- SYRE $17.38
- BAK $3.17
- Analyst Decision
- SYRE Buy
- BAK Strong Buy
- Analyst Count
- SYRE 5
- BAK 3
- Target Price
- SYRE $55.00
- BAK $9.75
- AVG Volume (30 Days)
- SYRE 490.8K
- BAK 871.5K
- Earning Date
- SYRE 08-05-2025
- BAK 08-07-2025
- Dividend Yield
- SYRE N/A
- BAK N/A
- EPS Growth
- SYRE N/A
- BAK N/A
- EPS
- SYRE N/A
- BAK N/A
- Revenue
- SYRE N/A
- BAK $14,266,076,929.00
- Revenue This Year
- SYRE N/A
- BAK $7.45
- Revenue Next Year
- SYRE N/A
- BAK $10.63
- P/E Ratio
- SYRE N/A
- BAK N/A
- Revenue Growth
- SYRE N/A
- BAK 10.48
- 52 Week Low
- SYRE $10.91
- BAK $2.80
- 52 Week High
- SYRE $40.26
- BAK $7.71
- Technical
- Relative Strength Index (RSI)
- SYRE 57.01
- BAK 52.94
- Support Level
- SYRE $15.73
- BAK $2.80
- Resistance Level
- SYRE $17.42
- BAK $3.03
- Average True Range (ATR)
- SYRE 0.89
- BAK 0.13
- MACD
- SYRE 0.07
- BAK 0.02
- Stochastic Oscillator
- SYRE 86.50
- BAK 69.81
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.